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Genetic Variations in NALP1 Are Associated with
Generalized Vitiligo in a Romanian Population
Ying Jin1,4, Stanca A. Birlea1,2,4, Pamela R. Fain1,3 and Richard A. Spritz1
Generalized vitiligo is a common, multifactorial, polygenic disease in which autoimmune loss of melanocytes
results in depigmented spots of skin, overlying hair, and mucous membranes. In Caucasian families from the
United States of America and United Kingdom, susceptibility to generalized vitiligo and associated autoimmune
diseases is genetically associated with variants of NALP1, encoding NACHT leucine-rich repeat protein 1. Here,
we describe a population-based case–control association analysis of single-nucleotide polymorphisms (SNPs)
distributed through the NALP1 region in Caucasian generalized vitiligo patients and controls from Romania.
This study confirms genetic association of generalized vitiligo with variation in NALP1, which contains at least
two independent risk signals, one tagged by SNP rs6502867 and another tagged by SNPs rs2670660 and
rs8182352. Individuals carrying high-risk alleles of both rs6502867 and rs2670660 had an odds ratio of 4.20
compared with individuals carrying a high-risk allele from only one signal. These findings support the
involvement of NALP1 in predisposition to generalized vitiligo.
Journal of Investigative Dermatology (2007) 127, 2558–2562; doi:10.1038/sj.jid.5700953; published online 19 July 2007
INTRODUCTION
Generalized vitiligo is an acquired, non-contagious disorder
in which progressive, patchy loss of pigmentation from skin,
overlying hair, and oral mucosa results from autoimmune loss
of melanocytes from the involved areas (Nordlund et al.,
2006). Vitiligo is perhaps the most common pigmentation
disorder, occurring in about 0.4% of Caucasians (Howitz
et al., 1977), with a similar prevalence in other populations.
Generalized vitiligo is a multifactorial, polygenic disorder,
resulting from complex interaction of multiple genes
(Majumder et al., 1993; Nath et al., 1994; Sun et al., 2006)
and unknown environmental triggers. There is frequent family
clustering of cases in a non-Mendelian pattern; probands’
first-degree relatives have 6–7% risk of developing generali-
zed vitiligo, and the concordance rate in monozygotic twins
is 23% (Alkhateeb et al., 2003). About 25–30% of generalized
vitiligo patients manifest at least another autoimmune
disease, particularly autoimmune thyroid disease (Graves
disease and autoimmune hypothyroidism), rheumatoid
arthritis, psoriasis, adult-onset autoimmune diabetes mellitus,
pernicious anemia, Addison’s disease, and systemic lupus
erythematosus (Alkhateeb et al., 2003; Laberge et al., 2005).
Furthermore, these same autoimmune diseases occur at
increased frequency in patients’ close relatives, even those
without vitiligo, suggesting that increased risk of these
autoimmune diseases has a genetic basis.
Several candidate genes have been tested for genetic
association with generalized vitiligo, including the MHC,
ACE, CAT, CTLA4, COMT, ESR, GCH1, MBL2, PTPN22, and
VDR (reviewed in Spritz, 2007a, b). Most of these studies
reported significant associations, although some yielded only
marginal significance and several were not replicated by
subsequent studies. We (Alkhateeb et al., 2002; Fain et al.,
2003; Spritz et al., 2004) and others (Nath et al., 2001; Chen
et al., 2005) have genetically mapped several chromosomal
regions that appear to contribute to vitiligo, on chromosomes
1p, 4q, 7, 8, 9, and 17p13. Very recently, we (Jin et al., 2007)
identified the 17p gene as NALP1, which encodes NACHT
leucine-rich repeat protein 1, a key regulator of the innate
immune system (Gregersen, 2007). In Caucasians from the
United States and the United Kingdom, at least two common
NALP1 variants appear to independently contribute to risk of
generalized vitiligo and other autoimmune diseases, one
located within the NALP1 structural gene and tagged by
single-nucleotide polymorphism (SNP) rs6502867, and an-
other located within a 65-kb linkage disequilibrium (LD)
block tagged by numerous SNPs in the proximal coding
region and the extended promoter region of NALP1 (Jin et al.,
2007).
To determine whether variation in NALP1 likewise
contributes to risk of vitiligo in other patient populations,
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we genotyped NALP1 region SNPs in 66 unselected patients
with typical generalized vitiligo from Romania and 93
unaffected controls from the same geographical region. We
observed significant genetic association of vitiligo with the
same high-risk alleles of the same NALP1 SNPs that were
previously associated with disease in the USA and UK
families (Jin et al., 2007). These results thus provide
independent support for association of NALP1 variants
with risk of generalized vitiligo in Caucasians of European
origin.
RESULTS
Characteristics of vitiligo patients and controls
We studied a total of 66 unrelated Caucasian patients with
generalized vitiligo and 93 unrelated Caucasian controls with
no autoimmune diseases, all from the same geographical
region of Romania (Table 1). There were no significant
differences (Po0.05) between cases and controls as to gender
or age. The mean age of vitiligo onset was 26.6717.1 years,
similar to in USA and UK Caucasian patients (Alkhateeb
et al., 2003). Among the 66 patients, 51 manifested vitiligo
vulgaris, 14 acrofacial vitiligo, and one vitiligo universalis.
Other autoimmune disorders occurred in 18 (27.2%) of these
patients, including autoimmune thyroid disease, rheumatoid
arthritis, adult-onset insulin-dependent diabetes mellitus,
pernicious anemia, and psoriasis.
Genetic association of NALP1 variants with vitiligo
We genotyped a total of eight SNPs distributed across 292 kb
of the NALP1 genomic region, including 224 kb of its
extended promoter region (Figure 1). One SNP
(rs12150220) deviated significantly (Po0.01) from Hardy–
Weinberg equilibrium among the controls and was therefore
excluded from further analyses (Balding, 2006). Three of the
seven remaining SNPs (rs6502867, rs2670660, and
rs8182352) had shown association with generalized vitiligo
and other autoimmune diseases in our previous study of USA
and UK families (Jin et al., 2007); the other four (rs8074853,
rs16954840, rs11078587, and rs1008588) were included to
sample additional variation across the NALP1 region of
chromosome 17p.
Allele and genotype frequency data for these seven NALP1
SNPs are summarized in Table 2. Six SNPs were frequent in
the study population, with minor allele frequencies among
the controls X30%; only rs16954840 was uncommon, with
minor allele frequency 5.4% among the controls. The three
SNPs tested that had shown genetic association with
generalized vitiligo in USA and UK families (Jin et al.,
2007), rs69502867, rs2670660, and rs8182352, also showed
association with vitiligo in the Romanian patient group.
Overall, the SNP with the most significant association was
rs2670660 (allelic association P¼ 0.039; genotypic associa-
tion P¼ 0.032). SNP rs6502867 was also associated with
vitiligo (allelic association P¼ 0.019), although genotypic
association was marginal (P¼ 0.058). SNP rs8182352 had
significant genotypic association (P¼ 0.034), although allelic
association was not significant. SNP rs8074853 showed
marginal genotypic association (P¼0.059). SNPs
rs16954840, rs11078587, and rs1008588 were not asso-
ciated with vitiligo.
Table 1. Demographic and clinical characteristics of
vitiligo cases and controls
Generalized
vitiligo (n=66)
Controls
(n=93)
Gender, n (%)
Male 24 (36.4) 35 (37.6)
Female 42 (63.6) 58 (62.4)
Age (years)
Mean (7SD) 45.0720.2 48.52720.5
Age of vitiligo onset (years)
Mean (7SD) 26.6717.1
Other associated autoimmune and autoinflammatory diseases, n (%)
Autoimmune thyroid disease 9 (13.6)
Rheumatoid arthritis 4 (6.0)
Adult-onset insulin-dependent
diabetes mellitus
3 (4.5)
Pernicious anemia 1 (1.5)
Psoriasis 1 (1.5)
Total 18 (27.2)
Family history of vitiligo, n (%) 21 (31.8)
SD, standard deviation.
Mb              5.36 5.37                   5.43                5.46                      5.50 5.64 5.65
5.37
This study
Jin et al. (2007)
rrr
s
6
5
0
2
8
6
7
r
s
1
1
0
7
8
5
8
7
r
s
1
0
0
8
5
8
8
r
s
8
1
8
2
3
5
2
r
s
2
6
7
0
6
6
0
ss
81
06
79
45
84
58
34
0
Figure 1. Association of NALP1 region SNPs with vitiligo. The seven SNPs
analyzed in this study and by Jin et al. (2007) are indicated; filled stars
indicate significantly associated SNPs, unfilled stars indicate marginally
associated SNPs, and open circles indicated SNPs with no apparent
association. The 21 exons of the NALP1 structural gene are indicated by the
black bars (transcriptional orientation shown from right to left). Nucleotide
positions (Mb) on chromosome 17p (National Center for Biotechnology
Information build 36) are indicated. tel, telomeric; cen, centromeric.
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Of the three SNPs that showed association with vitiligo,
rs2670660 and rs8182352 are within a block of strong LD,
whereas SNP rs6502867 is not in LD with them (data not
shown). These SNPs thus represent at least two independent
association signals, one tagged by rs6502867, and the other
tagged by rs2670660 and rs8182352, as we found previously
in USA and UK patients (Jin et al., 2007). To determine
whether individuals carrying high-risk alleles from both of
Table 2. Allele and genotype frequencies of NALP1 SNPs in the Romanian vitiligo patients and controls
Cases (n=66) Controls (n=93) OR (95% CI) P-valuea P-valueb
[G/A] rs6502867
GG 3 (0.05) 8 (0.09) 1.0 (referent)
GA 18 (0.27) 39 (0.42) 1.23 (0.29–5.19) 0.777
AA 45 (0.68) 46 (0.49) 2.61 (0.65–10.46) 0.176
Overall 0.058
High-risk allele: A% 81.8 70.4 1.86 (1.09–3.21) 0.019
[A/G] rs8074853
AA 11 (0.17) 30 (0.32) 1.0 (referent)
AG 41 (0.62) 43 (0.46) 2.60 (1.15–5.86) 0.021
GG 14 (0.21) 20 (0.22) 1.91 (0.72–5.04) 0.192
Overall 0.059
High-risk allele: G% 52.3 44.6 1.39 (0.87–2.21) 0.178
[T/C] rs16954840
TT 58 (0.88) 83 (0.89) 1.0 (referent)
TC 8 (0.12) 10 (0.11) 1.14 (0.43–3.08) 0.789
CC 0 0
Overall 0.789
High-risk allele: C% 6.1 5.4 1.14 (0.43–3.08) 0.795
[T/C] rs2670660
TT 9 (0.14) 29 (0.31) 1.0 (referent)
TC 34 (0.51) 37 (0.40) 2.96 (1.23–7.15) 0.016
CC 23 (0.35) 27 (0.29) 2.74 (1.08–6.97) 0.034
Overall 0.032
High-risk allele: C% 60.6 48.9 1.54 (1.03–2.39) 0.039
[A/G] rs8182352
AA 8 (0.12) 26 (0.28) 1.0 (referent)
AG 38 (0.58) 39 (0.42) 3.17 (1.28–7.86) 0.013
GG 20 (0.30) 28 (0.30) 2.32 (0.87–6.18) 0.092
Overall 0.034
High-risk allele: G% 59.1 51.1 1.38 (0.88–2.16) 0.157
[T/A] rs11078587
TT 21 (0.32) 28 (0.30) 1.0 (referent)
TA 29 (0.44) 46 (0.49) 0.84 (0.40–1.75) 0.642
AA 16 (0.24) 19 (0.21) 1.12 (0.47–2.69) 0.795
Overall 0.763
High-risk allele: A% 46.2 45.2 1.04 (0.67–1.61) 0.853
[C/T] rs1008588
CC 10 (0.15) 21 (0.22) 1.0 (referent)
CT 37 (0.56) 50 (0.54) 1.55 (0.65–3.69) 0.318
TT 19 (0.29) 22 (0.24) 1.81 (0.69–4.79) 0.230
Overall 0.460
High-risk allele: T% 56.8 50.5 1.32 (0.82–2.13) 0.268
SNP, single-nucleotide polymorphism.
P-values were obtained from Wald test of logistic regression model; odds ratios (OR) were calculated from the coefficients of the regression equation.
aGenotypic association P-value.
bAllelic association P-value.
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these two association signals have greater risk of vitiligo than
individuals carrying a high-risk allele from just one or the
other signal, we compared the number of patients and
controls with at least one high-risk allele of both rs6502867
(which tags one signal) and rs2670660 (which tags the other
signal) with the number of patients and controls carrying at
least one high-risk allele of only rs6502867 or rs2670660.
Overall, 57/66 (86.4%) of vitiligo patients carry high-risk
alleles from both of the two NALP1 association signals,
whereas 6/66 (9.1%) carry a high-risk allele from only one,
compared with 61/93 (65.6%) and 27/93 (29.0%), respec-
tively, among controls (P¼ 0.001). The odds ratio (OR) for
vitiligo among individuals carrying high-risk alleles from both
NALP1 association signals is 4.20 (95% confidence interval
1.62–10.93) compared with the reference group carrying a
high-risk allele from only one of the two signals. The
significance (P¼0.008) of the model that included both
rs6502867 and rs2670660 was greater than that of either
individual SNP, P¼ 0.019 and 0.039, respectively (this
improvement was significant; P¼ 0.032), and the haplotype
carrying both high-risk alleles conferred higher risk (OR 2.42,
95% confidence interval 1.27–4.87) than either individual
SNP (Table 2). This is consistent with our previous findings in
USA and UK vitiligo families (Jin et al., 2007).
Association between NALP1 variants and age of vitiligo onset
Linear regression analysis showed that the age of vitiligo
onset was negatively associated with carriage of the high-risk
A allele of SNP rs6502867 (P¼ 0.032). Carrying one high-risk
allele of rs6502867 decreased the age of disease onset by 6.8
years, and homozygosity for the high-risk A allele of
rs6502867 decreased the age of disease onset by 13.6 years.
Overall, 5.3% of the variance in age of disease onset could be
predicted by SNP rs6502867. No statistically significant
association was found between the other markers and the age
of vitiligo onset.
DISCUSSION
NALP1 is a key regulator of the innate immune system,
functioning as part of the surveillance system for infection by
bacteria or viruses. NALP1 is widely expressed, but is at
highest levels in Langerhans cells and T cells (Kummer et al.,
2007). Recognition of pathogen-associated molecular pat-
terns by NALP1, possibly muramyl dipeptide (Faustin et al.,
2007), is thought to stimulate assembly of the NALP1
inflammasome and thereby trigger inflammatory and apop-
totic pathways (reviewed in Gregersen, 2007).
We previously showed that variation in NALP1 is
associated both with risk of vitiligo and with risk of
epidemiologically associated autoimmune diseases in
families from the United States of America and United
Kingdom (Jin et al., 2007). NALP1 appears to contain at least
two independent high-risk variants that interact in a more-or-
less additive manner. Our current population-based case–
control study shows that NALP1 variants are likewise
associated with generalized vitiligo in a Romanian popula-
tion. Of the seven SNPs tested in NALP1 and its extended
promoter region (Figure 1), three, rs6502867, rs2670660, and
rs8182352, showed significant association with vitiligo in the
Romanian patients. These were some of the same SNPs,
involving the same high-risk alleles associated with disease in
the USA and UK families (Jin et al., 2007). SNP rs8074853,
located 6.8 kb upstream from rs6502867, was marginally
associated with disease in our previous study (Jin et al.,
2007), and was likewise marginally associated in this study.
SNP rs16954840, located just 3.2 kb further upstream,
showed no association with disease in either our previous
(Jin et al., 2007) or current study. Similarly, neither
rs11078587 nor rs1008588, both located more than 200 kb
upstream of the NALP1 structural gene, were associated with
disease in either study. The results are thus remarkably
concordant between the two studies, confirming association
of NALP1 with vitiligo.
SNP rs6502867 is located in an intron towards the 30 end
of the NALP1 gene, and by conditional logistic regression
analysis tags an independent association signal (Jin et al.,
2007); rs8074853 probably tags the same signal due to LD
with rs6502867. SNPs rs2670660 and rs8182352 are
located within a large block of strong LD and together tag
at least another independent association signal. The OR of
the haplotype defined by the high-risk alleles of both
6502867 and rs2670660 is greater than for either SNP
alone, and the OR for carriage of high-risk genotypes at
both rs6502867 and rs2670660, regardless of phase, is
even higher. Together, these results indicate that rs6502867
and rs2670660 tag independent signals with independent
effects on disease risk. We do not yet know which
NALP1 variants are causal for disease susceptibility,
which must await the results of future functional analyses,
and additional genes must also be involved in disease
pathogenesis.
MATERIALS AND METHODS
Subjects
All study subjects were recruited at Zalau Hospital (Zalau, Romania)
between January, 2005 and 2006. All were Caucasians from Salaj
county, northwestern Romania, and all were examined by S.A.B.
Diagnosis of generalized vitiligo was established using standard
diagnostic criteria (Nordlund et al., 2006), and excluded other
leukodermas. Clinical history of vitiligo and other autoimmune
diseases in patients was elicited by clinical interview. Absence of
vitiligo and other autoimmune diseases in controls was established
by clinical examination, history, and interview. Informed consent
was obtained from all subjects. This study was conducted according
to the Declaration of Helsinki Principles and was approved by the
Ethics Committee of ‘Iuliu Hatieganu’ University of Medicine and
Pharmacy (Cluj-Napoca, Romania) and COMIRB, University of
Colorado Health Sciences Center.
SNP Genotyping
Genomic DNAs were isolated from peripheral blood using the
Wizard Genomic DNA Purification Kit (Promega, Madison, WI).
PCRs were performed in 10 ml reaction volumes containing 20 ng
genomic DNA by standard methods. SNP alleles were detected
using the Applied Biosystems (ABI, Foster City, CA) PRISM SNaPshot
Multiplex Kit on an ABI3130XL DNA analyzer. Genotyping was
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performed automatically using GeneMapper software version 3.7
(ABI), with subsequent manual checking of accuracy.
Statistical analyses
Testing for Hardy–Weinberg equilibrium in the vitiligo patients and
controls, and calculation of LD between NALP1 region SNPs, was
performed using Haploview (Barrett et al., 2005), version 3.32.
Association between SNP and disease status was assessed by a Wald
test from a logistic regression model. For each marker, the allelic
association P-value was calculated using a model that assumed an
additive genotypic effect for the high-risk allele; and the genotypic
association P-value was calculated using a model that assumed no
particular mode of inheritance. Genotypic ORs were calculated from
the coefficients of the regression equation. For calculating genotypic
ORs for individual SNPs, we used the homozygotes carrying the low-
risk alleles as referent. Allelic haplotype analysis was performed
using the hapipf and profhap commands (Mander, 2001), which use
a log-linear model embedded within the expectation-maximization
algorithm. Haplotype frequencies for the phase-unknown samples
were calculated using the expectation-maximization algorithm, and
then a log-linear approach was used to assess the risk contributions
of haplotypes. To assess the effects of particular haplotypes, ORs and
confidence intervals were calculated. Linear regression analysis was
used to assess the relationship between each marker and the age of
vitiligo onset. The statistical analyses were carried out using STATA
software, version 9.2 (http://www.stata.com).
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